MargaretAnnShippMD

PubMed

• 2662 citations
  PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
  Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott
  The New England Journal of Medicine. 2015-01-21
• 575 citations
  The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
  Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Martinez, Steven H Swerdlow
  Blood. 2022-09-15
• 241 citations
  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
  Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine Pak, Sara Abdelrahman
  Journal of Clinical Oncology. 2018-02-02

Journal Articles

• Targeted Inhibition of PI3Kα/Δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL  
  Anthony Letai, Margaret A Shipp, Blood
• Publisher Correction: Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes  
  Thomas M Habermann, Scott J Rodig, Rameen Beroukhim, Jeremiah A Wala, Andrew L Feldman, Todd R Golub, Margaret A Shipp, Nature
• Mass Cytometry of Hodgkin Lymphoma Reveals a CD4+ Exhausted T-effector and T-regulatory Cell Rich Microenvironment  
  David Wu, Margaret A Shipp, Jonathan R Fromm, Philippe Armand, Scott J Rodig, Blood
• Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study  
  Younes A, Santoro A, Shipp MA, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen J, Collins G, Savage KJ, Trneny M, Kato K..., Lancet Oncology, 1/20/2016
• Using molecular signatures to identify rational therapeutic targets in diffuse large B-cell lymphoma  
  Chapuy B and Shipp M, Hematology Education: the education program for the annual congress of the European Hematology Association, 1/1/2009
• Molecular signatures define new rational treatment targets in large B-cell lymphomas  
  Shipp MA, Hematology Am Soc Hematol Education Program, 1/1/2007
• New concepts in treatment approaches and prognostic factors in aggressive NHL  
  Shipp MA, Clin Advances in Hematol & Oncol, 1/1/2006
• Advances in the biology and therapy of diffuse large B-cell lymphoma-moving towards a molecularly targeted approach  
  Abramson JS, Shipp MA, Blood, 1/1/2005
• Molecular heterogeneity of large B-cell lymphoma: an update  
  Shipp MA, European Hematology Association Educational Book, 1/1/2005
• Case Records of the Massachusetts General Hospital: A Thirty year old woman with fever and mediastinal mass  
  Shipp MA, N Engl J Med, 1/1/2005
• Molecular signatures of lymphoid Malignancies: Identification of novel disease subtypes and rational therapeutic targets  
  Shipp MA, ASH Educational Book, 1/1/2003
• Recent advances in the biology of diffuse large B-cell lymphoma  
  Shipp MA, ASCO Educational Book, 1/1/2003
• Report on the Workshop: "Clinical Consequences of Pathology and Prognostic Factors in Aggressive NHL"  
  Loeffler M, Shipp M, Stein H, Ann Hematol, 1/1/2001
• The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas  
  Howard OM, Shipp MA, Current Opinion Oncol, 1/1/1998
• NCCN preliminary non-Hodgkin's lymphoma practice guidelines  
  Shipp MA, Ambinder RF, Appelbaum FR, Cabanillas F, Harris NJ, Herzig GP, Hoppe RT, Horning SJ, Pezner RD, Rodriguez MA, Vose JM, Yahalom J, Zelenetz AD, Oncology (Williston Park), 1/1/1997
• Prognostic features in aggressive non-Hodgkin's lymphoma  
  Shipp MA, Gascoyne RD, Braziel RM, Grogan TM, Am J Surg Pathol, 1/1/1996
• Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission  
  Weeks JC, Yeap BY, Canellos GP, Shipp MA, ASCO "Classic Papers and Current Comments: Highlights of Clinical Lymphoma Research", 1/1/1996
• Inflammatory effector mechanisms in asthma  
  Drazen JM, Evans J, Stevens RI, Shipp MA, Amer J Resp and Critical Care Med, 1/1/1995
• A predictive model for non-Hodgkin's lymphoma, The Authors' Reply  
  Shipp MA, Harrington DP, N Engl J Med, 1/1/1994
• A predictive model for aggressive non-Hodgkin's lymphoma The international Non-Hodgkin's Lymphoma Prognostic Factors Project  
  Shipp M, Harrington D, Anderson J, Armitage J, Bonadonna G, Brittinger G, Cabanillas F et al, N Engl J Med, 1/1/1993
• Prognostic factors in non-Hodgkin's lymphoma  
  Shipp M, Current Opinion Oncol, 1/1/1992
• Patients with localized non-Hodgkin's lymphoma provide opportunities for further research [Commentary]  
  Shipp MA, Salles GS, Oncology, 1/1/1991
• CD10 (CALLA)/ Neutral endopeptidase 2411 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regula...  
  Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL, Blood, 1/1/1991
• CD10 (CALLA, common acute lymphoblastic leukemia antigen)/neutral endopeptidase 2411 (NEP, "enkephalinase"): Molecular structure and role in regulating met-enkephalin ...  
  Shipp MA, Stefano GB, Scharrer B, Reinherz EL, Adv in Neuroimmunol, 1/1/1991
• A possible immunoregulatory function for [Met]-enkephalin-Arg6-Phe7 involving human and invertebrate granulocytes  
  Stefano GB, Shipp MA, Scharrer B, J Neuroimmunol, 1/1/1991
• Join now to see all

Abstracts/Posters

• Validation of the Genetically-Defined DLBCL Subtypes and Generation of a Parsimonious Probabilistic Classifier
  Margaret A. Shipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
  Margaret A. Shipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade
  Margaret A. Shipp, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Changing the Taxonomy of Aggressive Lymphoma: Ready to Impact Clinical Management? 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all